Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ELVN 
Enliven Therapeutics Inc. (ELVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: ELVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $41.38
1 Year Target Price $41.38
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.49% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.25B USD | Price to earnings Ratio - | 1Y Target Price 41.38 |
Price to earnings Ratio - | 1Y Target Price 41.38 | ||
Volume (30-day avg) 8 | Beta 1.04 | 52 Weeks Range 13.30 - 25.96 | Updated Date 12/4/2025 |
52 Weeks Range 13.30 - 25.96 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.5 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.62% | Return on Equity (TTM) -25.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 743002837 | Price to Sales(TTM) - |
Enterprise Value 743002837 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.28 | Shares Outstanding 59347317 | Shares Floating 37327089 |
Shares Outstanding 59347317 | Shares Floating 37327089 | ||
Percent Insiders 8.21 | Percent Institutions 102.78 |
Upturn AI SWOT
Enliven Therapeutics Inc.
Company Overview
History and Background
Enliven Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing next-generation small molecule kinase inhibitors to address unmet needs in oncology. Founded in 2018, the company has rapidly advanced its pipeline with a focus on precision medicine approaches.
Core Business Areas
- Precision Oncology: Enliven develops targeted therapies for specific cancer mutations, focusing on kinase inhibitors.
Leadership and Structure
The leadership team includes experienced pharmaceutical executives and scientists. The company has a traditional organizational structure with departments focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- ELVN-3231 (FGFR Inhibitor): ELVN-3231 is a selective FGFR (fibroblast growth factor receptor) inhibitor being developed for patients with FGFR-altered cancers. Clinical trials are ongoing, so specific market share/revenue data is unavailable. Competitors include Incyte (Pemazyre), QED Therapeutics (Truseltiq), and Janssen (Balversa).
- ELVN-3106 (HER2 Inhibitor): ELVN-3106 is an EGFR inhibitor designed to address cancers with specific EGFR mutations. Clinical trials are ongoing, so specific market share/revenue data is unavailable. Competitors include AstraZeneca (Tagrisso), Takeda (Mobocertinib).
Market Dynamics
Industry Overview
The oncology market is characterized by high growth, driven by an aging population and advances in cancer diagnostics and treatment. Precision medicine approaches are gaining traction.
Positioning
Enliven is positioned as a precision oncology company focused on developing novel kinase inhibitors. Its competitive advantage lies in its expertise in kinase biology and drug discovery.
Total Addressable Market (TAM)
The global oncology market is projected to reach over $500 billion in the coming years. Enliven is targeting specific subsets of cancer patients with FGFR and EGFR alterations, representing a significant, but targeted, portion of the overall TAM.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise in kinase biology
- Promising pipeline of targeted therapies
- Experienced management team
- Focus on high unmet needs in oncology
Weaknesses
- Early-stage development pipeline
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
- Dependence on successful development and commercialization of its lead compounds
Opportunities
- Potential for breakthrough therapies in targeted oncology
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in diagnostics to identify more patients eligible for targeted therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays in drug approval
- Changes in healthcare reimbursement policies
- Patent expiration and generic competition
Competitors and Market Share
Key Competitors
- INCY
- JNJ
- AZN
- TAK
Competitive Landscape
Enliven faces competition from larger, established pharmaceutical companies. Its competitive advantage lies in its novel kinase inhibitors and focus on precision medicine.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's progress in advancing its pipeline and securing funding.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates will vary based on perceived probability of success.
Recent Initiatives: Recent initiatives include advancing ELVN-3231 and ELVN-3106 through clinical trials, presenting data at scientific conferences, and expanding the research pipeline.
Summary
Enliven Therapeutics is an early-stage biotech company with a promising pipeline of targeted oncology therapies. The company's strengths lie in its scientific expertise and focus on unmet medical needs. However, it faces significant risks related to clinical trial success and competition from larger pharmaceutical companies. Its future hinges on positive clinical data and successful commercialization of its lead compounds.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Enliven Therapeutics Inc. website, SEC filings, clinicaltrials.gov, analyst reports.
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enliven Therapeutics Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2020-03-12 | Co-Founder, CEO, Secretary & Director Mr. Samuel S. Kintz M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 65 | |
Full time employees 65 | |||
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.